Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/11/2012 | 09:06pm CET
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES, INC.
11:49a GILEAD SCIENCES : European Medicines Agency Validates Gilead’s Marketing A..
01/19 GILEAD SCIENCES : European Commission Grants Marketing Authorization for Gilead'..
01/19 GILEAD SCIENCES : Awards More Than $22 Million in Grants to Support HIV Cure Res..
01/19 GILEAD SCIENCES : Research Conducted at Gilead Sciences Inc. Has Provided New In..
01/18 MASTERCARD : and Gilead Sciences to Explore Digitized Healthcare Model in Resour..
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12 GILEAD SCIENCES : Alessandro Riva, MD, to Join Gilead as Senior Vice President, ..
01/11 GILEAD SCIENCES : European Commission Grants Marketing Authorization for Gilead&..
01/10 GILEAD SCIENCES : Awards More Than $22 Million in Grants to Support HIV Cure Res..
01/06 GILEAD SCIENCES : to Present at the 35th Annual J.P. Morgan Healthcare Conferenc..
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
04:21p Implications Of The Latest Smash In Bristol-Myers Squibb Stock
02:39p Why Gilead Is Undervalued
09:15a How I'm Positioning My Portfolio For 2017 (Ian Bezek)
06:47a EMA to review Gilead's marketing application for HCV med SOF/VEL/VOX
01/19 How Will Gilead Fare In 2017?
Advertisement
Financials ($)
Sales 2016 30 219 M
EBIT 2016 20 053 M
Net income 2016 13 945 M
Debt 2016 902 M
Yield 2016 2,59%
P/E ratio 2016 7,06
P/E ratio 2017 7,11
EV / Sales 2016 3,15x
EV / Sales 2017 3,30x
Capitalization 94 290 M
More Financials
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 96,8 $
Spread / Average Target 35%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-0.06%94 290
AMGEN, INC.5.19%114 415
CELGENE CORPORATION-1.84%88 079
REGENERON PHARMACEUTIC..-1.00%38 329
ACTELION LTD4.58%24 308
VERTEX PHARMACEUTICALS..9.83%20 068
More Results